EGFR and familial pancreatic carcinoma: Small molecule inhibitors that target the intracellular tyrosine kinase signaling pathways of EGFR, such as gefitinib (Iressa®) or erlotinib (Tarceva®) have been tested in clinical trials without major impact on the disease in spite of the fact that EGFR is over-expressed in 30–50% of pancreatic cancer [24]–[26].